A Single-Blind, Placebo-Controlled, Dose-Ranging Trial of Oral HDV-Insulin in Patients With Type 2 Diabetes Mellitus

NCT ID: NCT00521378

Last Updated: 2021-05-14

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 6 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2007-09-17
• Study Completion Date: 2007-10-06

Brief Summary

A study designed to determine the appropriate doses of Oral HDV Insulin at meal times.

Conditions

Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Eligibility Criteria

Inclusion Criteria

1. be male or female between the ages of18 and 65 years, inclusive;

2. have a current diagnosis of type 2 DM, which is currently managed with oral hypoglycemic agents for at least 3 months;

3. have a current physical examination that reveals no clinically significant abnormalities;

4. have no clinically significant abnormalities in vital signs;

5. have a body mass index (BMI) <38;

6. have a glycosylated hemoglobin (HbA1c) > 8 and <12;

7. have a C-peptide level >3 ng/mL;

8. have a typical fasting blood glucose levels of < 200 mg/dl (+/- 25 mg/dl);

9. be available for the entire study period, and be able and willing to adhere to protocol requirements;

10. if female of childbearing potential, must be using a reliable form of birth control; and,

11. provide written informed consent prior to admission into the study.

Exclusion Criteria

1. have a history or presence of significant cardiac, gastrointestinal, endocrine, neurological, liver, or kidney disease, or conditions known to interfere with the absorption, distribution, metabolism, or excretion of insulin;

2. have a history of drug or alcohol dependency or psychological disease;

3. have any clinically significant illness during the 4 weeks prior to admission into the study;

4. require regular use of medication that interferes with the absorption and/or metabolism of insulin;

5. recent use (within 48 hours) of medications that interfere with blood glucose analyses, i.e., mannose, acetaminophen, dopamine, and ascorbic acid, which are all reported to alter glucose-oxidase type blood glucose analytical methods;

6. use of Avandia or Actos for treating diabetes;

7. participation in a clinical trial or use of an investigational drug within 30 days prior to admission to this study;

8. use of MAO inhibitors or enzyme-inducing or enzyme-inhibiting agents (eg, phenobarbital or carbamazepine) within 30 days prior to admission to this study;

9. are pregnant or lactating; 10. have an episode of severe hypoglycemia with seizure or coma within the past year;

11. have a history of ketoacidosis;

12. have any acute illness within 2 weeks prior to Screening; or,

13. have elevated liver enzymes (ALT, AST, alkaline phosphatase) >1.5 times the upper limit of normal.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Diasome Pharmaceuticals

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

San Antonio, Texas, United States

Countries

United States

Other Identifiers

DP 01-2007-01

Identifier Type: -

Identifier Source: org_study_id